BIONET Corp. (TPEX:1784)

Taiwan · Delayed Price · Currency is TWD

45.90

-1.90 (-3.97%)

Nov 6, 2026, 1:30 PM CST

Market Cap	2.29B -57.6%
Revenue (ttm)	1.29B +5.4%
Net Income	57.18M -19.6%
EPS	1.14 -18.8%
Shares Out	49.83M
PE Ratio	40.34
Forward PE	n/a
Dividend	0.87 (1.90%)
Ex-Dividend Date	Oct 1, 2026

Volume	202,946
Open	44.00
Previous Close	47.80
Day's Range	43.05 - 47.50
52-Week Range	43.05 - 118.00
Beta	0.62
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About BIONET

BIONET Corp. engages in cell therapy, regenerative medicine, medical big data, gene testing, and sales of biological and scientific information hardware and software business in Taiwan and internationally. The company offers stem cell banking services, such as stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and PBSC and immune cells, as well as skin care products. It also provides storage and application of hematopoietic stem cells, analytical testing, clinical and preclinical research, commerciali... [Read more]

Industry Diagnostics & Research

Sector Healthcare

Founded 1989

Country Taiwan

Stock Exchange Taipei Exchange

Ticker Symbol 1784

Full Company Profile

Financial Performance

In 2025, BIONET's revenue was 1.24 billion, an increase of 1.19% compared to the previous year's 1.22 billion. Earnings were 51.43 million, a decrease of -38.56%.

Financial Statements